VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.

An announcement from CF PharmTech. Inc. Class H ( ($HK:2652) ) is now available. CF PharmTech announced that its company-led project to develop ...

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, ...

TheFly reported on December  16 that Oppenheimer raised its price target on WVE to $32 from $24 while maintaining an ...

Alnylam's $250 million investment will enhance its Norton, Massachusetts facility with an enzymatic ligation platform to meet ...

Veritas In Silico Inc. ( ($JP:130A) ) has issued an update. Veritas In Silico has filed a substance patent application in Japan for a ...

Hawaasa Afrikaa Kibbaa Afrikaanars Tiraamp ofitti fudhachuu fedhan maaltu kakaase? 'BBC Africa Eye' qorateera.

Dexoligo Therapeutics has presented data for their liver-targeted siRNA DXO-1801 for the potential treatment of inflammation-driven anemia, a serious complication of chronic diseases such as chronic ...

PeptiDream Inc. recently announced that its second oral peptide therapeutic program, a dual IL-17A and IL-17F macrocyclic inhibitor for autoimmune diseases, has entered its clinical development ...

A firm whose top investment ideas have beaten the broader market in 2025 unveiled the big themes and stocks to watch in the ...

SHANGHAI and SANTA BARBARA, Calif., Dec. 17, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the ...

In December 2025, Alnylam Pharmaceuticals announced a US$250 million expansion of its Norton, Massachusetts siRNA manufacturing facility and, together with PeptiDream, achieved a preclinical milestone ...